Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

BACKGROUND: The epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer has been successfully treated with tyrosine kinase inhibitors (TKIs). Acquired resistance becomes a tough issue when patients fail to respond to the third-generation TKI osimertinib. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Jin, Bo, Su, Hang, Qu, Xiujuan, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637526/
https://www.ncbi.nlm.nih.gov/pubmed/31315676
http://dx.doi.org/10.1186/s12885-019-5915-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637526/
https://www.ncbi.nlm.nih.gov/pubmed/31315676
http://dx.doi.org/10.1186/s12885-019-5915-7

Ejemplares similares